PRESS RELEASE published on 08/10/2026 at 08:30, 1 month 2 days ago Informations privilégiées / Autres communiqués Innate Pharma fait progresser Lacutamab vers la phase 3 suite au partenariat avec Sobi et nomme un nouveau directeur médical. Démarrage de l'étude TELLOMAK-3 pour le syndrome de Sézary Partenariat Phase 3 Innate Pharma Directeur Médical Lacutamab
BRIEF published on 05/19/2026 at 07:05, 3 months 24 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 3 months 24 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 3 months 24 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 3 months 24 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
PRESS RELEASE published on 05/19/2026 at 07:00, 3 months 24 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 3 months 24 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 4 months 24 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 4 months 24 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 4 months 24 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
Published on 09/12/2026 at 02:35, 11 hours 26 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 1 minute ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 56 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 36 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 1 minute ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 31 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 46 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 51 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 16 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 46 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
